Long-acting injectable risperidone as an option in first-episode psychosis.

Evid Based Ment Health

Psychiatry and Mental Health Services and Policy Research, Columbia University and New York State Psychiatric Institute, New York, New York, USA;

Published: May 2016

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10699429PMC
http://dx.doi.org/10.1136/eb-2015-102207DOI Listing

Publication Analysis

Top Keywords

long-acting injectable
4
injectable risperidone
4
risperidone option
4
option first-episode
4
first-episode psychosis
4
long-acting
1
risperidone
1
option
1
first-episode
1
psychosis
1

Similar Publications

The advent of once-weekly insulin icodec is a promising development in the care of individuals with diabetes. These once-weekly formulations aimed to improve patient adherence and quality of life for patients who find daily injection administration challenging. Insulin icodec has demonstrated comparable glycemic control to conventionally used daily basal insulins, such as insulin glargine and degludec, in the ONWARDS clinical trials.

View Article and Find Full Text PDF

Long-acting and extended-release drug delivery strategies have greatly improved treatment for a variety of medical conditions. Special populations, specifically infants, children, young people, and pregnant and postpartum women, could greatly benefit from access to these strategies but are often excluded from clinical trials. We conducted a systematic review of all clinical studies involving the use of a long-acting intramuscular injection or implant in infants, children, young people, and pregnant and postpartum people.

View Article and Find Full Text PDF

The development of novel long-acting injectables for local anesthetics is necessary to effectively manage the acute postoperative pain. The aim of this study was to prepare an injectable oil-based formulation of ropivacaine (ROP) prodrug (ropivacaine stearoxil, ROP-ST) and to investigate the pharmacokinetics and pharmacodynamics after injectable administration. A novel -acyloxymethyl prodrug of ROP, i.

View Article and Find Full Text PDF

Regulatory authorities typically require bioequivalence to be demonstrated by comparing pharmacokinetic parameters like area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C). Because in certain cases, AUC and C alone may not be adequate to identify formulation differences in early and/or late segments of the dosing interval, partial AUCs (pAUCs) have been proposed as additional metrics to evaluate bioequivalence. Even though cut-off points for pAUCs are usually decided based on clinical relevance, the identification of the correct cut-off range remains elusive in many other cases and tends to contribute to increased pAUC estimate variabilities.

View Article and Find Full Text PDF

Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone.

Children (Basel)

January 2025

Pediatric Research Center, New Children's Hospital, University of Helsinki, Helsinki University Hospital, 00290 Helsinki, Finland.

Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat, was first reported in 1999 and linked to antibody formation. In 2021, localized lipoatrophy was observed in 14.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!